Form 4: Monopar Therapeutics COO Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition of stock options and restricted stock units in a recent SEC filing.
Summary
- Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, filed a Form 4 with the SEC.
- The filing reports the acquisition of 43,445 stock options at an exercise price of $31.70, vesting over four years starting June 30, 2025.
- Additionally, 40,581 restricted stock units (RSUs) were acquired, vesting over four years starting June 30, 2025.
- Following these transactions, Cittadine directly owns 51,655 shares of Monopar Therapeutics.
- The filing also includes a confirming statement authorizing Quan A. Vu, Chandler D. Robinson, John Harrington, Sean Cheatle, Samuel Toth, and Brittany Stevenson to execute Section 16(a) reports on Cittadine's behalf.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option and RSU grants, which doesn't inherently indicate positive or negative sentiment. The grants could be seen as a positive sign of alignment between management and shareholders, but it's not a strong signal.
Positives
- The acquisition of stock options and RSUs by the COO could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules of the options and RSUs suggest a long-term commitment from the COO.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and management's stake in the company.
Stakeholder Impact
- The acquisition of stock options and RSUs by the COO aligns his interests with those of the shareholders, potentially incentivizing him to improve the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the reported transactions (acquisition of stock options and RSUs). |
| 03/07/2025 | Date of the Form 4 filing. |
| 06/30/2025 | Vesting start date for both stock options and RSUs. |
| 03/04/2035 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.